enigmasite homepage above footer backupohoto.png

ABOUT US

Most of us know someone who has had cancer or who has died from cancer. Some statistics suggest that 1 to 2 people in 10 will get cancer in their lifetime. It is a scary thought, that 1 to 2 people in 10 of our friends and family may get cancer. Cancer does NOT care what your job title is, how old you are, where you are from, how educated you are, whether you are: a mum, a dad, a child, a king, a queen, you’re rich, you’re famous. No one is immune to its effects.

Whilst much work has been done on cancer, and encouraging progress has been made, there are still a number of cancers that are difficult to treat, especially if they are diagnosed late. Cancers where treatments exist often need better ways of treating them.

At Enigma, we are working to unlock technology that fundamentally cripples how cancer operates. That means going back to the drawing board and finding weaknesses in the cancer process that can be exploited as treatments that are effective on even hard-to-treat cancers.

This means doing things that have not been done before.

Each member of the Enigma team including our academic collaborators are accomplished and distinguished professionals in their chosen field. Everyone without exception has put their personal interests aside to work in this team to achieve results for the greater good of each and everyone of us. We are driven by cutting edge science, asking the right questions, building solid foundations, setting good goals, challenging ourselves to succeed and then making sure we move forward.

Our mission is to develop effective medicines that change the way cancer is treated whilst lifting the burden of side effects to start a revolution against cancer.

Management Team

Berni Hambleton

Chief Executive Officer

Berni's has 25 years experience working in the Pharmaceutical and Biotech Industry, helping build companies and assets around therapeutic technology.

She is a European Patent Attorney and Chartered UK Patent Attorney and founded practices in UK and Singapore.

She has experience in finance, processes management, people management and training, compliance, contracts, and risk management.​

She is a co-founder of Enigma Immuno Therapeutics.

Patrick Hextall

Chief Technology Officer

Patrick has many years of experience gained in cutting edge science with Pharmaceutical and Biotech companies.

He worked work at Cambridge Antibody Technology and for a number has years has worked helping biotech companies designing therapeutic antibodies, developing and controlling commercial manufacturing processes for therapeutics, raise money and due diligence.

He is an inventor of the Enigmatrix technology and co-founder of Enigma Immuno Therapeutics.

Brian Champion

Chief Scientific Officer

Brian is a specialist in the field of immunology, including: cancer, autoimmune disease, allergy and vaccines.

He has worked for big Pharma and Biotech companies in both the UK and US and is an inventor on a number important therapeutic patents.

In additionto his scientific expertise he understand the drug development process, intellectual property and is a real people person supporting team members and helping younger ones develop.

Brian is a co-founder of Enigma Immuno Therapeutics

A word from the CEO, Berni Hambleton:

“I am super proud of the Enigma team including collaborators. It gives me confidence we will achieve our goal of making a difference in the fight against cancer”

Board of Directors

  • Prof Bertil Lindmark, Scientific Advisory Board (Pharma/Biotech RnD)

    Prof Bertil Lindmark

  • Dr Norman Barton, Scientific Advisory Board (Brain Cancer + RnD)

    Dr Norman Barton

  • Dr. Terry Hermiston, Scientific Advisory Board (Pharma/Biotech)

    Dr Terry Hermiston

SCIENTIFIC ADVISORY BOARD MEMBERS:

Prof Carlo Cantile

Prof Giunio Bruto Cherubini

Prof Dean Fennell

Dr David Humphreys

Prof Kaz Ito

Dr MarK McHale

Prof Miriam Moffat

Prof William Cookson